Gyre Therapeutics, Inc. GYRE Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The official record: Gyre Therapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Gyre Therapeutics, Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Gyre Therapeutics, Inc.'s operating cash flow?
- Gyre Therapeutics, Inc. (GYRE) reported operating cash flow of $3.18M in Q1 2026.
- How has Gyre Therapeutics, Inc.'s operating cash flow changed year-over-year?
- Gyre Therapeutics, Inc.'s operating cash flow increased by 2565.1% year-over-year, from -$129K to $3.18M.
- What is the long-term trend for Gyre Therapeutics, Inc.'s operating cash flow?
- Over 2 years (2021 to 2023), Gyre Therapeutics, Inc.'s operating cash flow has grown at a -44.4% compound annual growth rate (CAGR), from -$83.76M to $25.89M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.